SAREPTA THERAPEUTICS Q2 2017 EARNINGS CONFERENCE CALL
FORWARD-LOOKING STATEMENT

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "may," "intends," "prepares," "looks," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements by management relating to Sarepta's future operations, financial performance and projections, business plans, priorities and research and development programs including: the timing of Sarepta's 10-Q filing for Q1 2017; Sarepta's new CEO's ability to build upon Sarepta's success and to drive value for the company going forward, the transition in leadership being seamless and the former CEO continuing serving as a Board member; the impact of the agreements with BioMarin, including them granting Sarepta broad freedom to operate for its exon-skipping compounds; Sarepta's plan to expand its MAP and the revenue expectation associated with this program; Sarepta's anticipation that the launch of EXONDYS 51 will continue to progress successfully in the rest of 2017; the update to Sarepta's full-year revenue guidance and the belief that Sarepta is well-positioned for future growth; the commitment to support the success of EXONDYS 51 and rapidly advancing Sarepta's clinical pipeline, including through collaborations with third parties, and the potential of our product candidates, programs and technologies, such as PPMO; the timing of and plans to work with EMA through their review process of Sarepta's MAA, including collecting data and conducting additional studies and analysis; the status of and projected timelines for clinical studies, including entering the clinic, patient enrollment, opening new sites, data availability, study design and its potential benefits, and presentation of results; Sarepta's goals and ability to execute these goals including treating as many patients with DMD as possible; the benefits of the MidCap credit facility and Sarepta being committed to maintaining a strong balance sheet in the near and long term; the U.S. market size for potential beneficiaries of EXONDYS 51; Sarepta's expectations regarding the impact of port use by patients, re-authorizations, Sarepta education programs on genetic testing, sale trends continuing and discussions with payers on prescriptions, START Forms, patients starting on therapy and reimbursement landscape for EXONDYS 51; and Sarepta's plans to continue to build global infrastructure.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to EXONDYS 51 sales or attain the net revenues we anticipate for 2017, profitability or positive cash-flow from operations; we may not be able to establish and successfully conduct a MAP in one or more countries, and even if such program(s) are successfully conducted, we may not achieve any significant revenues; we may not be able to comply with all FDA post-approval commitments and requirements with respect to EXONDYS 51 in a timely manner or at all; we may not be able to obtain regulatory approval for EXONDYS 51 in jurisdictions outside of the U.S. including from the EMA for various reasons including any inability on our end to satisfactorily respond to their requests during the review process for our MAA; we may not be able to complete clinical trials required by the FDA or other regulatory authorities for approval of any of our product candidates; the results of our ongoing research and development efforts and clinical trials for our product candidates and product candidates being developed through third party collaborations may not be positive or consistent with prior results or demonstrate a safe treatment benefit; the transition to a new CEO may have a negative impact on the Company and its business plans; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, clinical development plans, and bringing our product candidates to market, for various reasons including possible limitations of Company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; our rights to commercialize EXONDYS 51 and our follow-on exons across the world may not be fully protected by our patents and/or third party agreements and those risks identified under the heading "Risk Factors" in Sarepta's most recent Annual Report on Form 10-K for the year ended December 31, 2016 or most recently filed Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.